The pharmacy is governed by a denser, more overlapping stack of standards than almost any other department in a hospital — a layered web of compendial chapters, design guidelines, building codes, accreditation expectations, and state licensure rules that all bear on the same rooms at the same time. This article maps that regulatory landscape: what each standard says at a programmatic level, who enforces it, how the layers stack and conflict, and how a project team manages the most-stringent-governs principle through design, construction, certification, and licensure. It is the governance companion to the engineering Articles in this Part — the cleanroom HVAC, the USP <797>/<800> suites, the controlled-substance vault, and the certification/sampling commissioning — which describe how the rooms are built and proven; this Article describes the rules that say they must be.

The regulatory stack at a glance

No single authority owns the pharmacy. Compliance is the intersection of five distinct layers, each with its own author, legal force, and enforcer:

The defining feature of this stack is that the layers are simultaneous, not sequential. A sterile-compounding room must satisfy USP <797> air-classification and FGI/ASHRAE 170 ventilation and NFPA 101 egress and the local building code and the State Board of Pharmacy's licensure inspection — all at once, on the same square footage. The project team's job is to reconcile them, and where they differ, to apply the most stringent applicable requirement.

USP <797> — sterile compounding

USP General Chapter <797>, Pharmaceutical Compounding — Sterile Preparations, is the foundational standard for any preparation of compounded sterile preparations (CSPs): IV admixtures, syringes, ophthalmics, epidurals, TPN, and the like. It is a patient-safety standard — its purpose is to prevent contamination (microbial, particulate, endotoxin) and to limit the time a CSP may be used before its sterility can no longer be assured.

What <797> drives in the building:

• Air classification and segregation. Sterile compounding occurs in a primary engineering control (PEC) — typically an ISO Class 5 laminar-airflow workbench, biological safety cabinet, or compounding aseptic isolator — sited within a secondary engineering control (SEC), the cleanroom suite. The buffer room (where the PEC lives) and the ante-room carry defined ISO air classifications, and the chapter sets the framework that the engineering Articles translate into HEPA filtration, air-change rates, and pressure cascades.
• Categories and beyond-use dating (BUD). <797> sorts CSPs into categories (in the current revision, Category 1, Category 2, and Category 3, plus immediate-use) with beyond-use dates that depend on the compounding environment, sterility testing, and storage. The compounding environment a facility builds directly determines which BUDs — and therefore which workflows and inventory turns — are achievable. A facility that wants longer BUDs must build to a higher environmental standard and add sterility/endotoxin testing.
• Personnel competency and monitoring. Gowning, hand hygiene, garbing competency, media-fill testing, gloved-fingertip sampling, and surface/air viable sampling are all mandated. These translate into anteroom design, gowning-flow sequencing, and the environmental-sampling program that becomes part of commissioning and ongoing operations.
• Cleaning, certification, and master formulation/compounding records round out the operational requirements.

USP <797> has been revised significantly over its history. The most consequential point for a project team is that <797> is not self-enforcing — it becomes mandatory only when a State Board of Pharmacy adopts it (most do, sometimes with state-specific amendments) or when an accreditor surveys to it. Always confirm which edition the governing Board has adopted, because boards adopt on their own timelines and a facility can be legally held to an older or newer revision than the current published chapter.

USP <800> — hazardous drug compounding and handling

USP General Chapter <800>, Hazardous Drugs — Handling in Healthcare Settings, is a worker- and environment-protection standard, distinct in purpose from <797>'s patient-protection focus. It governs the receipt, storage, compounding, dispensing, administration, and disposal of hazardous drugs (HDs) — most prominently antineoplastics (chemotherapy), but also the broader NIOSH Hazardous Drug List, which includes many non-antineoplastic hazardous and reproductive-risk drugs.

What <800> drives in the building:

• Containment-primary engineering controls (C-PEC) in containment-secondary engineering controls (C-SEC). HD sterile compounding occurs in a containment cabinet (e.g., a Class II biological safety cabinet or compounding aseptic containment isolator) within a negative-pressure cleanroom — the opposite pressure relationship from the positive-pressure non-hazardous sterile suite. This negative/positive split is the single most architecturally consequential feature of <800> and is detailed in the hazardous-compounding and HVAC Articles.
• Externally vented, often single-pass air. C-PECs handling HDs are required to be externally exhausted, which drives dedicated exhaust risers, roof discharge, and frequently 100% outside-air (single-pass) design for the HD suite.
• Storage and receiving controls. HDs must be stored separately, and a negative-pressure HD storage room is required where the inventory warrants it; receiving and unpacking of HDs carry their own containment and spill-response requirements.
• The Assessment of Risk (AoR). <800> permits a facility, for certain dosage forms and final-dosage manipulations, to document an Assessment of Risk that defines alternative containment strategies rather than full <800> engineering controls. The AoR is a critical scoping document: it determines how much negative-pressure cleanroom a facility must actually build, and it should be settled by Pharmacy and the Board's expectations before the suite is designed, not after.